Sierra Oncology, Inc. – NASDAQ:SRRA

Sierra Oncology stock price today

$54.99

Sierra Oncology stock price monthly change

+0.38%
month

Sierra Oncology stock price quarterly change

+67.14%
quarter

Sierra Oncology stock price yearly change

+182.44%
year

Sierra Oncology key metrics

Market Cap
N/A
Enterprise value
884.51M
P/E
-8.34
EV/Sales
N/A
EV/EBITDA
-8.63
Price/Sales
N/A
Price/Book
4.40
PEG ratio
-1.14
EPS
-6.77
Revenue
N/A
EBITDA
-102.40M
Income
-102.67M
Revenue Q/Q
N/A
Revenue Y/Y
-100%
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Sierra Oncology stock price history

Sierra Oncology stock forecast

Sierra Oncology financial statements

Sierra Oncology, Inc. (NASDAQ:SRRA): Profit margin
Jun 2021 0 -20.63M
Sep 2021 0 -28.64M
Dec 2021 0 -25.46M
Mar 2022 0 -27.92M
Sierra Oncology, Inc. (NASDAQ:SRRA): Earnings per share (EPS)
2021-11-05 -1.78 -2.1
2022-03-10 -1.54 -1.67
2022-05-06 -1.03 -1.33
Sierra Oncology, Inc. (NASDAQ:SRRA): Debt to assets
Jun 2021 94377000 10.11M 10.71%
Sep 2021 104227000 9.17M 8.8%
Dec 2021 109367000 13.36M 12.22%
Mar 2022 280000000 18.37M 6.56%
Sierra Oncology, Inc. (NASDAQ:SRRA): Cash Flow
Jun 2021 -17.00M -40K 113K
Sep 2021 -29.74M 0 36.15M
Dec 2021 -15.25M -32K 22.95M
Mar 2022 -25.73M -62K 195.06M

Sierra Oncology alternative data

Sierra Oncology, Inc. (NASDAQ:SRRA): Employee count
Aug 2023 109
Sep 2023 109
Oct 2023 109
Nov 2023 109
Dec 2023 109
Jan 2024 109
Feb 2024 109
Mar 2024 109
Apr 2024 109
May 2024 109
Jun 2024 109
Jul 2024 109

Sierra Oncology other data

Sierra Oncology, Inc. (NASDAQ:SRRA): Insider trades (number of shares)
Period Buy Sel
May 2021 5000 0
Nov 2021 13500 0
Jan 2022 1900000 7000
Feb 2022 350000 12000
Mar 2022 0 5553
Apr 2022 0 8447
Transaction Date Insider Security Shares Price per share Total value Source
Option
TURNER WILLIAM D. officer: Chief Reg & Tech Ops O..
Stock Option (Right to Buy) 6,347 $12.05 $76,481
Sale
TURNER WILLIAM D. officer: Chief Reg & Tech Ops O..
Common Stock 6,347 $37.25 $236,407
Option
TURNER WILLIAM D. officer: Chief Reg & Tech Ops O..
Common Stock 6,347 $12.05 $76,481
Sale
TURNER WILLIAM D. officer: Chief Reg & Tech Ops O..
Common Stock 100 $37.09 $3,709
Option
TURNER WILLIAM D. officer: Chief Reg & Tech Ops O..
Common Stock 100 $12.05 $1,205
Option
THOMSON MARY CHRISTINA officer: General Counsel, CCO &..
Stock Option (Right to Buy) 2,000 $13.04 $26,080
Sale
THOMSON MARY CHRISTINA officer: General Counsel, CCO &..
Common Stock 2,000 $35.14 $70,276
Option
THOMSON MARY CHRISTINA officer: General Counsel, CCO &..
Common Stock 2,000 $13.04 $26,080
Option
TURNER WILLIAM D. officer: Chief Reg & Tech Ops O..
Stock Option (Right to Buy) 100 $12.05 $1,205
Sale
TURNER WILLIAM D. officer: Chief Reg & Tech Ops O..
Common Stock 100 $37.05 $3,705
Patent
Application
Filling date: 13 May 2020 Issue date: 21 Jul 2022
Application
Filling date: 26 Mar 2020 Issue date: 16 Jun 2022
Application
Filling date: 28 Aug 2019 Issue date: 23 Dec 2021
Application
Filling date: 21 Aug 2019 Issue date: 30 Sep 2021
Application
Filling date: 10 Apr 2018 Issue date: 18 Mar 2021
Application
Filling date: 26 Feb 2019 Issue date: 24 Dec 2020
Application
Filling date: 1 Jun 2018 Issue date: 21 May 2020
Insider Compensation
Dr. Stephen George Dilly M.B.B.S, Ph.D. (1960) Pres, Chief Executive Officer & Director
$778,950
Dr. Barbara J. Klencke M.D. (1957) Chief Medical Officer $706,250
Dr. Mark M. Kowalski M.D., Ph.D. (1955) Chief of Research & Early Devel. $629,030
Thursday, 2 June 2022
Zacks Investment Research
Thursday, 14 April 2022
Stockmarketcom
Wednesday, 13 April 2022
Invezz
InvestorPlace
Benzinga
Schaeffers Research
Barrons
The Motley Fool
Benzinga
Pulse2
Market Watch
Reuters
Friday, 28 January 2022
Seeking Alpha
Thursday, 27 January 2022
Business Wire
Wednesday, 26 January 2022
Seeking Alpha
Tuesday, 25 January 2022
Invezz
Benzinga
The Motley Fool
Friday, 3 September 2021
Business Wire
  • What's the price of Sierra Oncology stock today?

    One share of Sierra Oncology stock can currently be purchased for approximately $54.99.

  • When is Sierra Oncology's next earnings date?

    Unfortunately, Sierra Oncology's (SRRA) next earnings date is currently unknown.

  • Does Sierra Oncology pay dividends?

    No, Sierra Oncology does not pay dividends.

  • What is Sierra Oncology's stock symbol?

    Sierra Oncology, Inc. is traded on the NASDAQ under the ticker symbol "SRRA".

  • What is Sierra Oncology's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Sierra Oncology?

    Shares of Sierra Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Sierra Oncology's key executives?

    Sierra Oncology's management team includes the following people:

    • Dr. Stephen George Dilly M.B.B.S, Ph.D. Pres, Chief Executive Officer & Director(age: 65, pay: $778,950)
    • Dr. Barbara J. Klencke M.D. Chief Medical Officer(age: 68, pay: $706,250)
    • Dr. Mark M. Kowalski M.D., Ph.D. Chief of Research & Early Devel.(age: 70, pay: $629,030)
  • How many employees does Sierra Oncology have?

    As Jul 2024, Sierra Oncology employs 109 workers.

  • When Sierra Oncology went public?

    Sierra Oncology, Inc. is publicly traded company for more then 10 years since IPO on 16 Jul 2015.

  • What is Sierra Oncology's official website?

    The official website for Sierra Oncology is sierraoncology.com.

  • Where are Sierra Oncology's headquarters?

    Sierra Oncology is headquartered at 2150 ? 885 West Georgia Street, Vancouver, BRITISH COLUMBIA.

  • How can i contact Sierra Oncology?

    Sierra Oncology's mailing address is 2150 ? 885 West Georgia Street, Vancouver, BRITISH COLUMBIA and company can be reached via phone at +1 604 558 6536.

Sierra Oncology company profile:

Sierra Oncology, Inc.

sierraoncology.com
Exchange:

NASDAQ

Full time employees:

109

Industry:

Biotechnology

Sector:

Healthcare

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.

2150 ? 885 West Georgia Street
Vancouver, BRITISH COLUMBIA 94404

CIK: 0001290149
ISIN: US82640U4040
CUSIP: 82640U404